Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 5/20 | 0.46 |
| ▸ | CSNK1G2 | P78368 | 5/20 | 0.46 |
| ▸ | GSK3B | P49841 | 4/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3301830 | 0.83 | LPL (0.38) | RIPK1CSNK1DCSNK1A1CSNK1G2GSK3B | |
| SCHEMBL3765301 | 0.79 | NPC1 (0.52) | MEN1KMT2AHDAC6LPLLIPG | |
| SCHEMBL22085181 | 0.78 | LMNA (0.52) | GSK3BRAF1MEN1KMT2APOLB | |
| SCHEMBL15574354 | 0.76 | ALDH1A1 (0.49) | MEN1KMT2ALPLLIPGPOLB | |
| SCHEMBL20732668 | 0.76 | TBK1 (0.40) | — | |
| SCHEMBL3761817 | 0.76 | GAA (0.55) | RIPK1EGFRPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL15296449 | 0.75 | EGFR (0.40) | EGFRLPLLIPGSMN1; SMN2 | |
| SCHEMBL3831957 | 0.75 | PLAU (0.47) | EGFRMEN1KMT2ALPLLIPG | |
| SCHEMBL18236211 | 0.74 | ADORA2A (0.64) | RIPK1CSNK1DCSNK1A1CSNK1G2GSK3B | |
| SCHEMBL9718864 | 0.74 | RIPK1 (0.63) | RIPK1CSNK1DCSNK1A1CSNK1G2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365566-B2 | Cinnoline derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365566-B2 | Cinnoline derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365566-B2 | Cinnoline derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20150038510-A1 | CINNOLINE DERIVATIVES | TAKEDA CALIFORNIA, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038510-A1 | CINNOLINE DERIVATIVES | TAKEDA CALIFORNIA, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038510-A1 | CINNOLINE DERIVATIVES | TAKEDA CALIFORNIA, INC. | 2015-02-05 | — | — | US | disclosed |
| EP-2435435-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-01-29 | — | — | EP | disclosed |
| WO-2013148603-A1 | CINNOLINE DERIVATIVES AS AS BTK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013148603-A1 | CINNOLINE DERIVATIVES AS AS BTK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-03 | — | — | WO | disclosed |
| US-8536180-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2010138575-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | IGF1R, TK1, CDK2 | RIPK1 1697/4885CSNK1D 224/4885CSNK1A1 81/4885 |
| US-20150038510-A1 | CINNOLINE DERIVATIVES | BTK, LYN, ABL1 | RIPK1 1579/4885CSNK1D 38/4885CSNK1A1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.